Y Intercept Hong Kong Ltd Reduces Holdings in Insulet Co. (NASDAQ:PODD)

Y Intercept Hong Kong Ltd cut its stake in shares of Insulet Co. (NASDAQ:PODD) by 69.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,286 shares of the medical instruments supplier’s stock after selling 2,986 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Insulet were worth $336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the business. Venturi Wealth Management LLC lifted its stake in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the period. TD Private Client Wealth LLC increased its position in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial bought a new position in Insulet during the 4th quarter valued at approximately $57,000. Blue Trust Inc. increased its position in Insulet by 117.3% during the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $72,000 after buying an additional 149 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 157 shares in the last quarter.

Insulet Trading Up 0.1 %

Shares of PODD stock opened at $272.64 on Tuesday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock’s 50-day moving average price is $274.20 and its 200-day moving average price is $251.26. The stock has a market capitalization of $19.15 billion, a price-to-earnings ratio of 47.09, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Equities research analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on PODD shares. StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a report on Tuesday. Morgan Stanley raised their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. BTIG Research raised their price target on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Sanford C. Bernstein initiated coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Finally, TD Cowen lifted their target price on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $289.06.

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.